SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Sun Pharmaceutical Industries’ Mohali facility

16 Aug 2022 Evaluate

United States Food and Drug Administration (USFDA) has concluded an inspection at Sun Pharmaceutical Industries’ Mohali manufacturing facility (Punjab, India) from August 3, 2022 to August 12, 2022. At the conclusion of the inspection, the USFDA issued a Form 483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to US FDA within the stipulated timeline. The company is committed to address these observations promptly. The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×